It belongs to a class of medications called GLP-1 receptor agonists, which work by mimicking a hormone that regulates hunger and insulin
Treatment with Wegovy usually begins with a lower dose that is increased gradually
Who May Benefit from Dual-Action Therapy Versus GLP-1 Monotherapy Dual-agonist therapy may be appropriate for patients with type 2 diabetes, prediabetes, or obesity who have inadequate response to GLP-1 monotherapy or require more aggressive metabolic intervention
For example, patients losing more than 10% of body weight over several months may demonstrate higher gallstone incidence
Common adverse effects include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort
Compounded products have less margin